Platelet-activating Factor Antagonist-based Intensive Antiplatelet Strategy in Acute Ischemic Stroke: A Propensity Score Matched with Network Pharmacology Analysis

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2023 Jul 12

PMID 37435773

Authors

Xiaoyan Han

Youjia Li

Xuemin Chen

Dong Pan

Junning Mo

Jiaming Qiu

Yi Li

Yan Chen

Yan Huang

Qingyu Shen

Yamei Tang

Affiliations

Soon will be listed here.

Abstract

Background: Diterpene ginkgolides meglumine injection (DGMI) is a platelet-activating factor receptor (PAFR) antagonist that can be used to treat acute ischemic stroke (AIS). This study evaluated the efficacy and safety of an intensive antiplatelet strategy based on PAFR antagonists and explored the underlying mechanisms of PAFR antagonists in AIS treatment.

Methods: This is a retrospective study applying propensity score methods to match AIS patients treated with DGMI to nontreated patients. The primary outcome was functional independence (modified Rankin Scale [mRS] 0-2) at 90 days. The safety outcome was bleeding risk. We used McNemar test to compare the efficacy outcome. Subsequently, the network pharmacology analysis was performed.

Results: 161 AIS patients treated with DGMI in the study were matched with 161 untreated patients. Compared with untreated patients, DGMI-treated patients had a significantly higher rate of mRS ranking 0-2 at 90 days (82.0% vs. 75.8%, p < 0.001), without increased risk of bleeding. The gene enrichment analysis showed that the overlap genes of DGMI targeted and AIS-related enriched in thrombosis and inflammatory-related signaling pathways.

Conclusions: An intensive antiplatelet strategy of DGMI plus traditional antiplatelet agents is effective in treating AIS and may work by mediating post-stroke inflammation and thrombosis.

Citing Articles

Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.

Li M, Huo X, Chang Q, Liu X, Zhang J, Mao Z Front Pharmacol. 2024; 15:1475021.

PMID: 39575393 PMC: 11578817. DOI: 10.3389/fphar.2024.1475021.

Efficacy and safety of Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke with large vessel occlusion: a subgroup analysis of GIANT.

Zhang Z, Zhong W, Zhang X, Ma X, Lu X, Zhang M Front Pharmacol. 2024; 15:1452174.

PMID: 39281272 PMC: 11392837. DOI: 10.3389/fphar.2024.1452174.

Platelet-activating factor antagonist-based intensive antiplatelet strategy in acute ischemic stroke: A propensity score matched with network pharmacology analysis.

Han X, Li Y, Chen X, Pan D, Mo J, Qiu J CNS Neurosci Ther. 2023; 29(12):4082-4092.

PMID: 37435773 PMC: 10651968. DOI: 10.1111/cns.14331.

References

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

Ospel J, Holodinsky J, Goyal M . Management of Acute Ischemic Stroke Due to Large-Vessel Occlusion: JACC Focus Seminar. J Am Coll Cardiol. 2020; 75(15):1832-1843. DOI: 10.1016/j.jacc.2019.10.034. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Zhu J, Jin Z, Yang L, Zhao C, Hu J, Chen J . Ginkgolide B targets and inhibits creatine kinase B to regulate the CCT/TRiC-SK1 axis and exerts pro-angiogenic activity in middle cerebral artery occlusion mice. Pharmacol Res. 2022; 180:106240. DOI: 10.1016/j.phrs.2022.106240. View

Goyal N, Tsivgoulis G, Zand R, Sharma V, Barlinn K, Male S . Systemic thrombolysis in acute ischemic stroke patients with unruptured intracranial aneurysms. Neurology. 2015; 85(17):1452-8. PMC: 4631074. DOI: 10.1212/WNL.0000000000002068. View

Campbell B, De Silva D, Macleod M, Coutts S, Schwamm L, Davis S . Ischaemic stroke. Nat Rev Dis Primers. 2019; 5(1):70. DOI: 10.1038/s41572-019-0118-8. View

Yi X, Wang C, Liu P, Fu C, Lin J, Chen Y . Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population. J Neurol. 2016; 263(8):1612-9. DOI: 10.1007/s00415-016-8181-5. View

Dong Y, Zhang J, Wang Y, Zhao L, Li R, Wei C . Effect of Ginkgolide in Ischemic Stroke patients with large Artery Atherosclerosis: Results from a randomized trial. CNS Neurosci Ther. 2021; 27(12):1561-1569. PMC: 8611772. DOI: 10.1111/cns.13742. View

Han X, Li Y, Chen X, Pan D, Mo J, Qiu J . Platelet-activating factor antagonist-based intensive antiplatelet strategy in acute ischemic stroke: A propensity score matched with network pharmacology analysis. CNS Neurosci Ther. 2023; 29(12):4082-4092. PMC: 10651968. DOI: 10.1111/cns.14331. View

10.

Lyden P, Raman R, Liu L, Grotta J, Broderick J, Olson S . NIHSS training and certification using a new digital video disk is reliable. Stroke. 2005; 36(11):2446-9. DOI: 10.1161/01.STR.0000185725.42768.92. View

11.

Bath P, Woodhouse L, Appleton J, Beridze M, Christensen H, Dineen R . Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2017; 391(10123):850-859. PMC: 5854459. DOI: 10.1016/S0140-6736(17)32849-0. View

12.

Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3):e46-e110. DOI: 10.1161/STR.0000000000000158. View

13.

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

14.

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(1):11-9. DOI: 10.1056/NEJMoa1215340. View

15.

Gunning G, McArdle K, Mirza M, Duffy S, Gilvarry M, Brouwer P . Clot friction variation with fibrin content; implications for resistance to thrombectomy. J Neurointerv Surg. 2017; 10(1):34-38. DOI: 10.1136/neurintsurg-2016-012721. View

16.

Ponomarev E, Maresz K, Tan Y, Dittel B . CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci. 2007; 27(40):10714-21. PMC: 6672829. DOI: 10.1523/JNEUROSCI.1922-07.2007. View

17.

Wang Y, Liu M, Pu C . 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack. Int J Stroke. 2017; 12(3):302-320. DOI: 10.1177/1747493017694391. View

18.

Yang Y, Zhou Z, Pan Y, Chen H, Wang Y . Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design. Am Heart J. 2020; 225:38-43. DOI: 10.1016/j.ahj.2020.04.003. View

19.

Johnston S, Easton J, Farrant M, Barsan W, Conwit R, Elm J . Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018; 379(3):215-225. PMC: 6193486. DOI: 10.1056/NEJMoa1800410. View

20.

Khadankhuu B, Fei Y, Li X, Fang W, Li Y . 10-O-(N N-Dimethylaminoethyl)-Ginkgolide B Methane-Sulfonate (XQ-1H) Ameliorates Cerebral Ischemia Via Suppressing Neuronal Apoptosis. J Stroke Cerebrovasc Dis. 2021; 30(9):105987. DOI: 10.1016/j.jstrokecerebrovasdis.2021.105987. View